{
    "info": {
        "nct_id": "NCT06028438",
        "official_title": "A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of Concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis Despite Prior Treatment With Advanced Therapies (bDMARD or tsDMARD)",
        "inclusion_criteria": "* Diagnosis of rheumatoid arthritis (RA) and meeting the 2010 American college of rheumatology (ACR) or European League Against Rheumatism (EULAR) criteria for RA for at least 3 months before screening\n* Has moderate to severe active RA as defined by persistent disease activity with at least 6 of 66 swollen joints and 6 of 68 tender joints at the time of screening and at baseline\n* Is positive for anti-citrullinated protein antibodies (ACPA) or rheumatoid factor (RF) by the central laboratory at the time of screening\n* Has C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram per deciliter (mg/dL) by the central laboratory at the time of screening\n* If has received prior biological disease-modifying antirheumatic drugs (bDMARDs) (or biosimilars) other than anti-tumor necrosis factor (anti-TNF) agent in RA, has demonstrated inadequate response (IR) or intolerance to the therapy based on one of the following:\n\n  1. IR to at least 1bDMARD (or the biosimilars) other than anti-TNF agents, as assessed by the treating physician, after at least 12 weeks of therapy including but not limited to abatacept, anakinra, tocilizumab, and sarilumab or at least 16 weeks of therapy with rituximab Documented IR may include inadequate improvement or loss in response after initial improvement in joint counts or other parameters of disease activity\n  2. Intolerance to bDMARD (or biosimilars) other than anti-TNF agent, as assessed by the treating physician. Documented intolerance includes side effects and injection or infusion reactions\n* If has received prior anti-TNF agent (including biosimilars), has demonstrated IR to >=1 anti-TNF agent (including biosimilars), as assessed by the treating physician:\n\n  1. After at least 12 weeks dosage of etanercept, adalimumab, golimumab (including biosimilars), and/or\n  2. After at least 14 weeks dosage (example, at least 4 doses) of infliximab (including biosimilars) Documented IR may include inadequate improvement or loss in response after initial improvement in joint counts or other parameters of disease activity\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
        "exclusion_criteria": "* Has a confirmed or suspected clinical immunodeficiency syndrome not related to treatment of RA or has a family history of congenital or hereditary immunodeficiency unless confirmed absent\n* Is (anatomically or functionally) asplenic\n* Has experienced myocardial infarction, unstable ischemic heart disease, or stroke less than or equal to (<=) 12 weeks of screening\n* Has a diagnosis of congestive heart failure including medically controlled, asymptomatic congestive heart failure\n* Has a history of known demyelinating disease such as multiple sclerosis or optic neuritis",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. After at least 12 weeks dosage of etanercept, adalimumab, golimumab (including biosimilars), and/or",
            "criterions": [
                {
                    "exact_snippets": "After at least 12 weeks dosage of etanercept, adalimumab, golimumab (including biosimilars)",
                    "criterion": "etanercept, adalimumab, golimumab (including biosimilars) dosage duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of rheumatoid arthritis (RA) and meeting the 2010 American college of rheumatology (ACR) or European League Against Rheumatism (EULAR) criteria for RA for at least 3 months before screening",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of rheumatoid arthritis (RA)",
                    "criterion": "rheumatoid arthritis diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "meeting the 2010 American college of rheumatology (ACR) or European League Against Rheumatism (EULAR) criteria for RA",
                    "criterion": "2010 ACR or EULAR criteria for RA",
                    "requirements": [
                        {
                            "requirement_type": "meets_criteria",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for at least 3 months before screening",
                    "criterion": "duration of meeting RA criteria",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. After at least 14 weeks dosage (example, at least 4 doses) of infliximab (including biosimilars) Documented IR may include inadequate improvement or loss in response after initial improvement in joint counts or other parameters of disease activity",
            "criterions": [
                {
                    "exact_snippets": "After at least 14 weeks dosage (example, at least 4 doses) of infliximab (including biosimilars)",
                    "criterion": "infliximab (including biosimilars) treatment",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "number of doses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "doses"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented IR may include inadequate improvement or loss in response after initial improvement in joint counts or other parameters of disease activity",
                    "criterion": "inadequate response to infliximab",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "inadequate improvement or loss in response after initial improvement in joint counts or other parameters of disease activity"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 75 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 75 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If has received prior anti-TNF agent (including biosimilars), has demonstrated IR to >=1 anti-TNF agent (including biosimilars), as assessed by the treating physician:",
            "criterions": [
                {
                    "exact_snippets": "has received prior anti-TNF agent (including biosimilars)",
                    "criterion": "prior anti-TNF agent exposure",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has demonstrated IR to >=1 anti-TNF agent (including biosimilars)",
                    "criterion": "inadequate response to anti-TNF agent",
                    "requirements": [
                        {
                            "requirement_type": "inadequate response",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "anti-TNF agent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed by the treating physician",
                    "criterion": "assessment by treating physician",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "treating physician"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram per deciliter (mg/dL) by the central laboratory at the time of screening",
            "criterions": [
                {
                    "exact_snippets": "C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram per deciliter (mg/dL) ... at the time of screening",
                    "criterion": "C-reactive protein (CRP) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.3,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has moderate to severe active RA as defined by persistent disease activity with at least 6 of 66 swollen joints and 6 of 68 tender joints at the time of screening and at baseline",
            "criterions": [
                {
                    "exact_snippets": "moderate to severe active RA",
                    "criterion": "rheumatoid arthritis (RA)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "persistent disease activity",
                    "criterion": "disease activity",
                    "requirements": [
                        {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 6 of 66 swollen joints",
                    "criterion": "swollen joint count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "joints"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "6 of 68 tender joints",
                    "criterion": "tender joint count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "joints"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at the time of screening and at baseline",
                    "criterion": "timing of joint counts",
                    "requirements": [
                        {
                            "requirement_type": "timepoints",
                            "expected_value": [
                                "screening",
                                "baseline"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is positive for anti-citrullinated protein antibodies (ACPA) or rheumatoid factor (RF) by the central laboratory at the time of screening",
            "criterions": [
                {
                    "exact_snippets": "Is positive for anti-citrullinated protein antibodies (ACPA) ... by the central laboratory at the time of screening",
                    "criterion": "anti-citrullinated protein antibodies (ACPA)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "test location",
                            "expected_value": "central laboratory"
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at the time of screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Is positive for ... rheumatoid factor (RF) by the central laboratory at the time of screening",
                    "criterion": "rheumatoid factor (RF)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "test location",
                            "expected_value": "central laboratory"
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at the time of screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Intolerance to bDMARD (or biosimilars) other than anti-TNF agent, as assessed by the treating physician. Documented intolerance includes side effects and injection or infusion reactions",
            "criterions": [
                {
                    "exact_snippets": "Intolerance to bDMARD (or biosimilars) other than anti-TNF agent, as assessed by the treating physician",
                    "criterion": "intolerance to bDMARD (or biosimilars) other than anti-TNF agent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment",
                            "expected_value": "as assessed by the treating physician"
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented intolerance includes side effects and injection or infusion reactions",
                    "criterion": "side effects and injection or infusion reactions to bDMARD (or biosimilars) other than anti-TNF agent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. IR to at least 1bDMARD (or the biosimilars) other than anti-TNF agents, as assessed by the treating physician, after at least 12 weeks of therapy including but not limited to abatacept, anakinra, tocilizumab, and sarilumab or at least 16 weeks of therapy with rituximab Documented IR may include inadequate improvement or loss in response after initial improvement in joint counts or other parameters of disease activity",
            "criterions": [
                {
                    "exact_snippets": "IR to at least 1bDMARD (or the biosimilars) other than anti-TNF agents",
                    "criterion": "inadequate response to at least one bDMARD (excluding anti-TNF agents)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed by the treating physician",
                    "criterion": "assessment by treating physician",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": "treating physician"
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least 12 weeks of therapy including but not limited to abatacept, anakinra, tocilizumab, and sarilumab",
                    "criterion": "duration of therapy with specified bDMARDs (abatacept, anakinra, tocilizumab, sarilumab)",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "drug",
                            "expected_value": [
                                "abatacept",
                                "anakinra",
                                "tocilizumab",
                                "sarilumab"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "or at least 16 weeks of therapy with rituximab",
                    "criterion": "duration of therapy with rituximab",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "drug",
                            "expected_value": "rituximab"
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented IR may include inadequate improvement or loss in response after initial improvement in joint counts or other parameters of disease activity",
                    "criterion": "documented inadequate response (IR)",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "response",
                            "expected_value": [
                                "inadequate improvement",
                                "loss in response after initial improvement"
                            ]
                        },
                        {
                            "requirement_type": "parameters",
                            "expected_value": [
                                "joint counts",
                                "other parameters of disease activity"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If has received prior biological disease-modifying antirheumatic drugs (bDMARDs) (or biosimilars) other than anti-tumor necrosis factor (anti-TNF) agent in RA, has demonstrated inadequate response (IR) or intolerance to the therapy based on one of the following:",
            "criterions": [
                {
                    "exact_snippets": "has received prior biological disease-modifying antirheumatic drugs (bDMARDs) (or biosimilars) other than anti-tumor necrosis factor (anti-TNF) agent in RA",
                    "criterion": "prior bDMARDs (or biosimilars) use (excluding anti-TNF agents) in RA",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug class",
                            "expected_value": "bDMARDs (or biosimilars) other than anti-TNF agents"
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "rheumatoid arthritis (RA)"
                        }
                    ]
                },
                {
                    "exact_snippets": "has demonstrated inadequate response (IR) or intolerance to the therapy",
                    "criterion": "response or tolerance to prior bDMARDs (or biosimilars) therapy",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "inadequate"
                        },
                        {
                            "requirement_type": "tolerance",
                            "expected_value": "intolerant"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has a diagnosis of congestive heart failure including medically controlled, asymptomatic congestive heart failure",
            "criterions": [
                {
                    "exact_snippets": "Has a diagnosis of congestive heart failure",
                    "criterion": "congestive heart failure diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including medically controlled, asymptomatic congestive heart failure",
                    "criterion": "congestive heart failure status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "medically controlled",
                                "asymptomatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has experienced myocardial infarction, unstable ischemic heart disease, or stroke less than or equal to (<=) 12 weeks of screening",
            "criterions": [
                {
                    "exact_snippets": "Has experienced myocardial infarction ... less than or equal to (<=) 12 weeks of screening",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Has experienced ... unstable ischemic heart disease ... less than or equal to (<=) 12 weeks of screening",
                    "criterion": "unstable ischemic heart disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Has experienced ... stroke less than or equal to (<=) 12 weeks of screening",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a confirmed or suspected clinical immunodeficiency syndrome not related to treatment of RA or has a family history of congenital or hereditary immunodeficiency unless confirmed absent",
            "criterions": [
                {
                    "exact_snippets": "Has a confirmed or suspected clinical immunodeficiency syndrome not related to treatment of RA",
                    "criterion": "clinical immunodeficiency syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "relation to RA treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "has a family history of congenital or hereditary immunodeficiency unless confirmed absent",
                    "criterion": "family history of congenital or hereditary immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation of absence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is (anatomically or functionally) asplenic",
            "criterions": [
                {
                    "exact_snippets": "(anatomically or functionally) asplenic",
                    "criterion": "asplenia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "anatomical",
                                "functional"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of known demyelinating disease such as multiple sclerosis or optic neuritis",
            "criterions": [
                {
                    "exact_snippets": "history of known demyelinating disease",
                    "criterion": "demyelinating disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple sclerosis",
                    "criterion": "multiple sclerosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "optic neuritis",
                    "criterion": "optic neuritis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}